Abstract:INTRODUCTION AND OBJECTIVES: According to data from SEER (http://seer.cancer.gov/) in the United States, bladder cancer (BC) has improved 5-year survival rate by only 3% in the last two decades.D-3-phosphoglycerate dehydrogenase (PHGDH) is an enzyme that converts 3-phosphoglycerate on glycolysis system and induces metabolism to serine synthesis.Cancers require serine to maintain rapid, sustained and uncontrollable proliferation.Recently it has been reported that PHGDH can be a therapeutic target in breast cancer and melanoma, on the other hand there has been no report on BC.The aim of this study is to evaluate therapeutic possibility regarding PHGDH in BC.METHODS: Clinical significance of PHGDH in BC was analyzed using The Cancer Genome Atlas (TCGA) which is a public database.In addition, the effect of PHGDH inhibitor (NCT-503) and si-RNA against PHGDH was evaluated by cell proliferation and apoptosis assay in BC cell lines (T24, BOY, KK47, UMUC-3, J82).In xenograft assay, PHGDH knockdown efficiency was investigated using sh-RNA against PHGDH.Furthermore, additive effect of the PHGDH inhibitor under Gemcitabine and Cisplatin (GC) administration was examined.RESULTS: In the PHGDH high expression group (n [ 157), the prognosis was poor (P [ 0.0032) compared with the low expression group (n [ 247), and PHGDH was found to be an independent poor prognostic factor (P [ 0.001) in multivariate analysis.The PHGDH inhibitor and PHGDH si-RNAs significantly inhibited proliferative ability through induction of apoptosis (P < 0.05) in BC cell lines.Western blot analyses showed that Ki-67 expression was markedly repressed and cleaved caspase-3 expression was increased in PHGDH knockdown BC cells compared with those in control BC cells.Additionally, cells with PHGDH overexpression promoted tumor cell viability in comparison to control cells.In xenograft assay, PHGDH knockdown by sh-RNA significantly inhibited tumor progression compared to the vehicle group (P < 0.05).Furthermore, the combination treatment between PHGDH inhibitor and GC showed synergistic tumor suppressive effect compared to each single agent group (P < 0.05) in proliferation assay.CONCLUSIONS: Our study revealed that PHGDH inhibition showed tumor suppressive effects in BC.Furthermore, the combination therapy between PHGDH inhibitor and GC showed synergistic effect in proliferation assay.Novel therapeutic implications through functional analysis of PHGDH in BC were suggested.

A retrospective overview of PHGDH and its inhibitors for regulating cancer metabolism

Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma

Identification of novel PHGDH inhibitors based on computational investigation: an all-in-one combination strategy to develop potential anti-cancer candidates

Rational Design of Selective Allosteric Inhibitors of PHGDH and Serine Synthesis with Anti-tumor Activity.

Recent advances in pyruvate dehydrogenase kinase inhibitors: Structures, inhibitory mechanisms and biological activities

MP51-06 SMYD3 INHIBITION INDUCES PROTECTIVE AUTOPHAGY IN BLADDER CANCER VIA MTOR PATHWAY

Phosphoglycerate Dehydrogenase Promotes Pancreatic Cancer Development by Interacting with Eif4a1 and Eif4e

The Emerging Roles of the Metabolic Regulator G6PD in Human Cancers

Structure‐Based Computational Approach in Search of the Potent Molecules Targeting Phosphoglycerate Dehydrogenase (PHGDH) Enzyme for Cancer Treatment

O-GlcNAcylation of G6PD Promotes the Pentose Phosphate Pathway and Tumor Growth

Targeting the ROS/PI3K/AKT/HIF‐1α/HK2 Axis of Breast Cancer Cells: Combined Administration of Polydatin and 2‐Deoxy‐d‐glucose

The Regulatory Mechanisms and Inhibitors of Isocitrate Dehydrogenase 1 in Cancer

Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies

Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation

Homoharringtonine as a PHGDH inhibitor: Unraveling metabolic dependencies and developing a potent therapeutic strategy for high-risk neuroblastoma

Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine

Inhibition of Phosphoglycerate Dehydrogenase Radiosensitizes Human Colorectal Cancer Cells under Hypoxic Conditions

6-Phosphogluconate dehydrogenase promotes glycolysis and fatty acid synthesis by inhibiting the AMPK pathway in lung adenocarcinoma cells

Transcriptional regulation and post-translational modifications in the glycolytic pathway for targeted cancer therapy

Regulation of the Pentose Phosphate Pathway in Cancer

Synthesis and Biological Evaluation of Anthraquinone Derivatives As Allosteric Phosphoglycerate Mutase 1 Inhibitors for Cancer Treatment.